BOSTON–epocrates, a digital information platform for healthcare professionals, has partnered with Glass Health to expand artificial intelligence-powered clinical decision support capabilities within its AI Assist platform, giving clinicians access to drug information and broader medical insights through a single conversational interface.
The partnership integrates Glass Health’s clinical AI model, Glass, into epocrates AI Assist, a conversational tool designed to help healthcare providers research clinical questions, retrieve relevant medical information and explore potential follow-up considerations without leaving the epocrates application.
The collaboration combines nearly 30 years of epocrates’ experience delivering drug information to clinicians with Glass Health’s technology for AI-driven clinical decision support.
According to the companies, the integration is intended to help physicians and other healthcare professionals access evidence-based medical information more efficiently during patient care.
“Clinicians have trusted epocrates for drug information for nearly 30 years, and that trust comes from getting the details right,” said David Minkin, President and General Manager of epocrates. “As clinicians bring broader questions to AI Assist, we wanted a partner held to the same standard. As we evaluated our options, Glass Health stood out for the quality of its answers and the evidence behind them. This partnership is another step in our ongoing investment in trusted, reliable answers clinicians can act on.”
epocrates selected Glass Health following an evaluation of several clinical AI providers. The assessment involved the company’s medical information team, including physicians and pharmacists, who examined the accuracy, reliability and clinical usefulness of the available technologies.
The evaluation also considered the quality of supporting medical evidence, performance on independent benchmarks against competing clinical decision support systems and compatibility with the existing AI Assist platform.
Glass Health develops artificial intelligence technology designed to assist clinicians with clinical reasoning, medical decision support and ambient documentation. Its technology uses AI models to analyze clinical questions and generate responses informed by medical evidence.
By incorporating the Glass model, epocrates aims to extend AI Assist beyond traditional drug reference information to support a wider range of clinical inquiries.
“The future of clinical AI is integrating state-of-the-art technology with the best available evidence,” said Dereck Paul, M.D., Co-Founder and Chief Executive Officer of Glass Health. “Clinicians have relied on epocrates for decades because of its commitment to accuracy and the quality of its clinical information. AI Assist reflects that same standard. We’re proud that Glass Health’s technology is helping power it, so clinicians can get relevant, evidence-based answers inside the app they already trust every day.”
The development of AI Assist involved research and testing with practicing clinicians to identify common information needs and improve the platform’s usability in clinical settings.
Feedback from healthcare professionals helped shape the conversational interface and its ability to provide relevant information during everyday medical decision-making.
The partnership comes as healthcare technology companies increasingly incorporate generative AI into clinical workflows to help medical professionals manage growing volumes of medical literature, treatment guidelines and patient-related information.
AI Assist, including the newly integrated Glass Health clinical decision support capabilities, is currently available to epocrates+ subscribers.
The company plans to expand access to all epocrates users over the coming weeks. The service will remain in beta during the broader rollout as the companies continue evaluating and refining its capabilities.
